705 related articles for article (PubMed ID: 25407896)
1. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
Gertz MA
Am J Hematol; 2011 Feb; 86(2):180-6. PubMed ID: 21264900
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2016 Sep; 91(9):947-56. PubMed ID: 27527836
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2020 Jul; 95(7):848-860. PubMed ID: 32267020
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
[TBL] [Abstract][Full Text] [Related]
9. [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
Charliński G; Jurczyszyn A; Wiktor-Jedrzejczak W
Przegl Lek; 2014; 71(2):102-9. PubMed ID: 25016786
[TBL] [Abstract][Full Text] [Related]
10. [Amyloid light chain amyloidosis].
Suzuki K; Shimizu T
Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
[TBL] [Abstract][Full Text] [Related]
11. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
12. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
14. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
15. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A; Dingli D; Kumar SK; Rajkumar SV; Lacy MQ; Hayman S; Buadi F; Zeldenrust S; Leung N; Detweiler-Short K; Lust JA; Russell SJ; Kyle RA; Gertz MA
Am J Hematol; 2010 Oct; 85(10):757-9. PubMed ID: 20872958
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
17. Systemic immunoglobulin light-chain amyloidosis.
Comenzo RL
Clin Lymphoma Myeloma; 2006 Nov; 7(3):182-5. PubMed ID: 17229332
[TBL] [Abstract][Full Text] [Related]
18. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
19. Light chain amyloidosis 2012: a new era.
Gatt ME; Palladini G
Br J Haematol; 2013 Mar; 160(5):582-98. PubMed ID: 23294331
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Palladini G; Russo P; Foli A; Milani P; Lavatelli F; Obici L; Nuvolone M; Brugnatelli S; Invernizzi R; Merlini G
Ann Hematol; 2012 Jan; 91(1):89-92. PubMed ID: 21533608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
